

CITATION REPORT

List of articles citing

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants

DOI: 10.1017/s1092852900020216

CNS Spectrums, 2009, 14, 197-206.

Source: <https://exaly.com/paper-pdf/45839982/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
235	New approaches to the pharmacological management of major depressive disorder. 2009 , 57, 347-79		11
234	Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. 2009 , 206, 335-44		38
233	The 5-HT ₇ receptor and disorders of the nervous system: an overview. 2009 , 206, 345-54		177
232	C.10.01 Life-long treatment in patients with schizophrenia. 2009 , 19, S712-S713		
231	C.10.02 Treating mania and managing long-term treatment of bipolar disorder. 2009 , 19, S713		
230	C.10.03 What is new in treating patients with major depressive disorder who show inadequate response to antidepressants. 2009 , 19, S713		
229	C.11.01 Multidimensional approach to sensory gating functions and cognition in humans. 2009 , 19, S713-S714		
228	Ritorno al futuro: gli antipsicotici atipici nella depressione resistente. 2009 , 28, 135-137		
227	Drs. Nelson and Papakostas Reply. 2010 , 167, 216-219		
226	A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole. 2010 , 30, 300-5		11
225	Bipolar depression: overview and commentary. 2010 , 18, 143-57		108
224	Comments on "Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials". 2010 , 32, 448; author reply 449		2
223	Comments on "Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials." Authors' response. 2010 , 32, 449		
222	Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence. 2010 , 9, 50-4		22
221	Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression. 2010 , 10, 651-70		15
220	Atypical Antipsychotics and Other Therapeutic Options for Treatment of Resistant Major Depressive Disorder. 2010 , 3, 3522-3542		6
219	Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects. 2010 , 5, 263-6		6

218	Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. 2010 , 122, 39-48	128
217	Therapeutic armamentarium for treating depression. 2010 , 122, 66-93	11
216	PW01-11 - Effect of adjunctive aripiprazole on quality of life in patients with major depressive disorder: pooled data from three clinical trials. 2010 , 25, 1427	
215	Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. 2010 , 13, 917-32	117
214	Second-generation antipsychotics for major depressive disorder and dysthymia. 2010 , CD008121	52
213	Therapeutic options for treatment-resistant depression. 2010 , 24, 131-61	141
212	The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior. 2010 , 209, 99-108	89
211	Accelerating response to antidepressant treatment in depression: a possible role for atypical antipsychotics. 2010 , 34, 434; author reply 435-6	1
210	Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. 2010 , 16, e1-17	93
209	P.2.c.031 Genotypic and phenotypic CYP2D6 poor metaboliser status in depressed patients treated with venlafaxine extended release. 2010 , 20, S385-S386	
208	P.2.c.032 Adjunctive aripiprazole in major depressive disorder (MDD): efficacy and predictors of remission. 2010 , 20, S386	
207	P.2.c.033 Influence and interaction of genetic polymorphisms in serotonin system and early life stress on antidepressant response. 2010 , 20, S386-S387	
206	Neuroprotection in Bipolar Depression. 2010 , 451-483	0
205	Antidepressant Compounds: A Critical Review. 2010 , 1-19	5
204	The Nature and Treatment of Therapy-Resistant Depression. 2010 , 243-253	
203	Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. 2010 , 11, 709-22	48
202	Consider augmentation or switching strategies when first-line antidepressants are unsuccessful in major depressive disorder. 2011 , 27, 7-12	
201	Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. 2011 , 25, 109-27	62

200	If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. 2011 , 71, 43-64		248
199	Safety considerations in drug treatment of depression in HIV-positive patients: an updated review. 2011 , 34, 623-39		26
198	P.2.a.005 Dosing of aripiprazole adjunctive therapy for Asian patients with major depressive disorder: a 24-week open label trial. 2011 , 21, S356-S357		
197	P.2.a.006 Plasma vascular endothelial growth factor (VEGF) and suicide risk. 2011 , 21, S357		
196	P.2.a.007 Quantifying rater drift on the HAM-D: implications for reliability, sample size, and ongoing training strategy. 2011 , 21, S357-S358		1
195	Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. 2011 , 7, 303-12		31
194	Major Depresif Bozukluk Tedavisinde Yetersiz Yanlı Yönetimi ve Yeni Tedavi Seçenekleri. 2011 , 21, S20-S25		
193	Current world literature. 2011 , 24, 78-87		
192	Second-generation antipsychotics in major depressive disorder: update and clinical perspective. 2011 , 24, 10-7		53
191	Serotonin 5-HT ₇ receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders. 2011 , 129, 120-48		141
190	Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder. <i>Journal of Affective Disorders</i> , 2011 , 128 Suppl 1, S3-10	6.6	42
189	Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness. <i>Journal of Affective Disorders</i> , 2011 , 128 Suppl 1, S11-20	6.6	24
188	Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis. <i>Journal of Affective Disorders</i> , 2011 , 133, 361-70	6.6	36
187	Therapeutic options in treatment-resistant depression. 2011 , 43, 512-30		58
186	Role of the 5-HT ₇ receptor in the central nervous system: from current status to future perspectives. 2011 , 43, 228-53		117
185	Aripiprazole augmentation in the treatment of military-related PTSD with major depression: a retrospective chart review. 2011 , 11, 86		8
184	Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. 2011 , 26, 564-72		35
183	National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders. 2011 , 168, 1057-65		55

182	Clozapine-induced lymphocytic alveolitis. 2011 , 168, 210-1	11
181	Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. 2011 , 100, 601-16	60
180	Targeting treatment-resistant depression. 2011 , 24, 520-33	12
179	Pharmacological blockade of 5-HT ₇ receptors as a putative fast acting antidepressant strategy. 2011 , 36, 1275-88	99
178	Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. 2012 , 27, 125-33	30
177	[Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy]. 2012 , 39, 57-63	4
176	Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms. 2012 , 16, 121-31	23
175	A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). 2012 , 81, 87-97	99
174	Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. 2012 , 27, 27-39	24
173	Contemporary concepts in the pharmacotherapy of depression in older people. 2012 , 145, 128-135.e2	3
172	P.5.e.004 Treatment of Alzheimer's disease: which effects on caregivers do we find?. 2012 , 22, S388-S389	
171	P.6.a.001 Augmentation therapy of aripiprazole with escitalopram in patients with co-occurrence of depression and alcohol dependence. 2012 , 22, S389	1
170	Emerging drugs for major depressive disorder. 2012 , 17, 105-26	60
169	The early improvement of depressive symptoms as a potential predictor of response to antidepressants in depressive patients who failed to respond to previous antidepressant treatments. Analysis of naturalistic data. 2012 , 27, 522-7	11
168	Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder. 2012 , 46, 642-9	8
167	The hidden third: improving outcome in treatment-resistant depression. <i>Journal of Psychopharmacology</i> , 2012 , 26, 587-602	4.6 49
166	Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder. 2012 , 39, 355-7	17
165	Sulpiride and refractory panic disorder. 2012 , 223, 247-9	5

164	Depression and schizophrenia. 2012 , 18, 280-288		7
163	Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. 2013 , 719, 25-33		88
162	Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression. 2013 , 27 Suppl 1, S11-9		34
161	Clinical issues in use of atypical antipsychotics for depressed patients. 2013 , 27 Suppl 1, S39-45		18
160	Management of chronic depressive patients with residual symptoms. 2013 , 27 Suppl 1, S53-7		11
159	Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. 2013 , 13, 851-70		65
158	Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. <i>Journal of Affective Disorders</i> , 2013 , 151, 209-19	6.6	51
157	Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy. 2013 , 13, 1183-200		6
156	Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy. 2013 , 65, 1535-44		32
155	Effects of lurasidone in behavioral models of depression. Role of the 5-HT _{2A} receptor subtype. 2013 , 70, 211-7		63
154	Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation Approach. 2013 , 2, 171-180		5
153	Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). <i>Journal of Affective Disorders</i> , 2013 , 151, 899-905	6.6	43
152	Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature. 2013 , 33, 344-59		53
151	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. 2013 , 14, 334-85		346
150	Serotonin receptors involved in antidepressant effects. 2013 , 137, 119-31		208
149	Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. 2013 , 10, e1001403		171
148	Antidepressant monotherapy compared with combinations of antidepressants in the treatment of resistant depressive patients: a randomized, open-label study. 2013 , 17, 35-43		7
147	Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study. 2013 , 28, 322-9		8

146	Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study. 2013 , 36, 157-61		12
145	Medical costs and hospitalizations among patients with depression treated with adjunctive atypical antipsychotic therapy: an analysis of health insurance claims data. 2013 , 47, 933-45		10
144	Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence. <i>Journal of Psychopharmacology</i> , 2013 , 27, 282-91	4.6	24
143	Future perspectives on the pharmacological management of depression. 2013 , 3, 137-151		
142	A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy. 2014 , 8, 189		58
141	Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder. 2014 , 47, 605-16		24
140	Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy. 2014 , 68, 1301-8		4
139	Pharmacological approaches to manage persistent symptoms of major depressive disorder: rationale and therapeutic strategies. 2014 , 220 Suppl 1, S15-33		17
138	How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine. 2014 , 29, 528-36		6
137	Use of augmentation agents for treating depression: analysis of a psychiatric electronic medical record data set. 2014 , 65, 1062-5		2
136	Use of atypical antipsychotics in the elderly: a clinical review. 2014 , 9, 1363-73		61
135	Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting. 2014 , 29, 116-9		7
134	The integrative management of treatment-resistant depression: a comprehensive review and perspectives. 2014 , 83, 70-88		75
133	High dose aripiprazole induced double incontinence. 2014 , 30, 361-362		2
132	Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy. <i>CNS Spectrums</i> , 2014 , 19, 528-34	1.8	11
131	Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis. <i>Journal of Affective Disorders</i> , 2014 , 162, 20-5	6.6	11
130	Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: a multi-center, naturalistic study. 2014 , 49, 75-82		16
129	Tratamiento farmacológico y terapia electroconvulsiva en la depresión unipolar; a propósito de un caso. 2014 , 21, 110-112		

128	Drug safety evaluation of olanzapine/fluoxetine combination. 2014 , 13, 1133-41		3
127	Dopamine receptor D3 deficiency results in chronic depression and anxiety. 2014 , 274, 186-93		47
126	Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study. 2014 , 7, 459		15
125	A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium. 2014 , 13, 1733-42		14
124	Comparing outcomes of adjunctive treatment in depression: aripiprazole versus bupropion. <i>Journal of Affective Disorders</i> , 2014 , 162, 50-4	6.6	3
123	Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study. 2014 , 221, 231-9		17
122	Treatment-resistant depression in primary care across Canada. 2014 , 59, 349-57		83
121	Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study. 2015 , 69, 34-42		20
120	The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. 2015 , 69, 1211-20		63
119	A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder. 2015 , 35, 319-23		11
118	The Role of Anger/Hostility in Treatment-Resistant Depression: A Secondary Analysis From the ADAPT-A Study. 2015 , 203, 762-8		13
117	Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice. 2015 , 51, 66-80		11
116	Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics. 2015 , 13, 616-35		30
115	Pharmacologic approaches to treatment resistant depression: Evidences and personal experience. 2015 , 5, 330-41		49
114	Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis. 2015 , 18, pyv060		107
113	Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study. 2015 , 66-67, 84-94		28
112	The effect of vortioxetine on health-related quality of life in patients with major depressive disorder. 2015 , 37, 2309-2323.e6		13
111	Do depressed patients on adjunctive atypical antipsychotics demonstrate a better quality of life compared to those on antidepressants only? A comparative cross-sectional study of a nationally representative sample of the US population. 2015 , 11, 228-40		3

110	Pharmacological treatment for generalized anxiety disorder in adults: an update. 2015 , 16, 1669-81	41
109	Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study. 2015 , 172, 1251-8	37
108	A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment. 2015 , 30, 167-74	20
107	Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials. 2015 , 18,	16
106	Antidepressant drug development: Focus on triple monoamine reuptake inhibition. <i>Journal of Psychopharmacology</i> , 2015 , 29, 526-44	4.6 27
105	Aripiprazole augmentation of antidepressants for postpartum depression: a preliminary report. 2015 , 18, 131-4	4
104	Symptoms of Anxiety and Irritability in Patients with Major Depressive Disorder. 2016 , 5,	2
103	Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. 2016 , 52, 159-72	36
102	Antipsychotics as antidepressants. 2016 , 8, 179-88	19
101	Comorbid Anxiety and Depressive Symptoms in Children and Adolescents: A Systematic Review and Analysis. 2016 , 22, 84-98	57
100	Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes. 2016 , 14, 244-265	2
99	Clinical application of DEX/CRH test and multi-channel NIRS in patients with depression. 2016 , 12, 25	11
98	RISK OF NEW ONSET TYPE II DM IN MDD PATIENTS RECEIVING SECOND-GENERATION ANTIPSYCHOTICS TREATMENT: A NATIONWIDE COHORT STUDY. 2016 , 33, 435-43	2
97	Current drug treatments targeting dopamine D3 receptor. 2016 , 165, 164-77	65
96	Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. 2016 , 16, 105	80
95	Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression. 2016 , 173, 107-11	45
94	[Potentiation strategies]. 2016 , 45, 338-49	1
93	Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study. 2017 , 37, 193-199	10

92	The Utility of Low-Dose Aripiprazole for the Treatment of Bipolar II and Bipolar NOS Depression. 2017 , 37, 99-101		10
91	Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. 2017 , 33, 701-711		44
90	The combination of escitalopram and aripiprazole: Investigation of psychomotor effects in rats. <i>Journal of Psychopharmacology</i> , 2017 , 31, 1605-1614	4.6	4
89	The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder. 2017 , 12, 1067-1081		4
88	Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. 2017 , 42, 844-853		72
87	Dopamine System Dysregulation in Major Depressive Disorders. 2017 , 20, 1036-1046		270
86	Increasing the Efficacy of the Psychopharmacotherapy of Late Depression: Optimization of Treatment Duration. 2017 , 47, 877-889		
85	Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies. 2018 , 14, 103-115		8
84	Anhedonia in depression and schizophrenia: A transdiagnostic challenge. 2018 , 24, 615-623		48
83	Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder. 2018 , 72, 591-601		4
82	Change in 1-year hospitalization of overall and older patients with major depressive disorder after second-generation antipsychotics augmentation treatment. <i>Journal of Affective Disorders</i> , 2018 , 230, 118-124	6.6	1
81	The influence of aripiprazole and venlafaxine on the antidepressant-like effect observed in prenatally stressed rats (animal model of depression). 2018 , 37, 972-982		3
80	Antidepressant Therapy for Depression: An Update. 2018 , 241-255		
79	Atypical Antipsychotics in Major Depressive Disorder. 2018 , 257-268		2
78	Meta-analysis and review of dopamine agonists in acute episodes of mood disorder: Efficacy and safety. <i>Journal of Psychopharmacology</i> , 2018 , 32, 385-396	4.6	20
77	Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression. 2018 , 33, 34-43		14
76	Korean Medication Algorithm for Depressive Disorders 2017: Third Revision. <i>Clinical Psychopharmacology and Neuroscience</i> , 2018 , 16, 67-87	3-4	27
75	Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial. 2018 , 33, 312-321		22

74	Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale. 2019 , 22, 173-179		9
73	An augmentation study of MSI-195 (S-adenosylmethionine) in Major Depressive Disorder. 2018 , 107, 86-96		6
72	Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder. 2018 , 34, 2105-2112		5
71	Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials. 2018 , 14, 467-477		7
70	The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review. 2019 , 22, 85-92		22
69	Hierarchical control systems for the regulation of physiological homeostasis and affect: Can their interactions modulate mood and anhedonia?. 2019 , 105, 251-261		11
68	Epidemiology of pharmaceutically treated depression and treatment resistant depression in South Korea. 2019 , 14, e0221552		10
67	Predictors of response to augmentation treatment in patients with treatment-resistant depression: A systematic review. <i>Journal of Psychopharmacology</i> , 2019 , 33, 1323-1339	4.6	9
66	Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. 2019 , 176, 428-438		282
65	Low- and high-dose aripiprazole augmentation and plasma levels of homovanillic acid in major depressive disorder: A randomized, open-label study. 2019 , 34, e2696		2
64	Effects of combined escitalopram and aripiprazole in rats: role of the 5-HT receptor. 2019 , 236, 2273-2281		3
63	Concurrent antipsychotic use in older adults treated with antidepressants in Asia. 2019 , 19, 333-339		5
62	Pharmacological interventions for treatment-resistant depression in adults. 2019 , 12, CD010557		14
61	Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2019 , 214, 42-51	5.4	44
60	Antidepressant-like activity and safety profile evaluation of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione derivatives as 5-HT1A receptor partial agonists. 2020 , 15, e0237196		2
59	Effect of Brexpiprazole on Prolactin and Sexual Functioning: An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder. 2020 , 40, 560-567		4
58	Efficacy and safety of TS-121, a novel vasopressin V receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study. 2020 , 128, 43-51		6
57	Relative effectiveness of augmentation treatments for treatment-resistant depression: a systematic review and network meta-analysis. 2020 , 32, 477-490		16

56	Pharmacological Treatments for Patients with Treatment-Resistant Depression. 2020 , 13,		36
55	Amitriptyline and Depressions. 2020 , 1-19		
54	Antidepressant Augmentation: A Review of the Literature and a Review of the Pharmacoeconomic Considerations. 2020 , 40, 396-400		3
53	Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression. <i>Journal of Affective Disorders</i> , 2021 , 280, 45-53	6.6	16
52	Monoaminergic system and antidepressants. 2021 , 345-355		0
51	Neuropharmacology. 2021 , 361-372.e2		
50	Is Obesity A Determinant Of Success With Pharmacological Treatment For Depression? A Systematic Review, Meta-Analysis And Meta-Regression. <i>Journal of Affective Disorders</i> , 2021 , 287, 54-68	6.6	8
49	Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?. 2021 , 22, 1669-1683		3
48	Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications. 2021 , 73, 1084-1117		6
47	Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. <i>Journal of Psychopharmacology</i> , 2021 , 35, 890-900	4.6	12
46	5-HT Receptors and the Development of New Antidepressants. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	7
45	Magnitude of the Placebo Response Across Treatment Modalities Used for Treatment-Resistant Depression in Adults: A Systematic Review and Meta-analysis. 2021 , 4, e2125531		8
44	The straw man of prescribing in psychiatry: Commentary on Drug-centred psychopharmacology. 2015 , 21, 237-239		1
43	Anatomical relationships between serotonin 5-HT _{2A} and dopamine D ₂ receptors in living human brain. 2017 , 12, e0189318		3
42	[An increase in the efficacy of psychopharmacotherapy of late-onset depressions: combination and substitution of antidepressants]. <i>Zhurnal Nevrologii I Psikiatrii Imeni S S Korsakova</i> , 2016 , 116, 43-51	0.4	2
41	National trends in second-generation antipsychotic augmentation for nonpsychotic depression. 2014 , 75, 490-7		30
40	Pharmacotherapy for late-life depression. 2011 , 72, e04		55
39	Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. <i>primary care companion for CNS disorders</i> , 2011 , 13,	1.2	9

38	Efficacy of adjunctive aripiprazole in major depressive disorder: a pooled response quartile analysis and the predictive value of week 2 early response. <i>primary care companion for CNS disorders, The</i> , 2012 , 14,	1.2	5
37	Improvement in functional outcomes with adjunctive aripiprazole versus placebo in major depressive disorder: a pooled post hoc analysis of 3 short-term studies. <i>primary care companion for CNS disorders, The</i> , 2012 , 14,	1.2	3
36	Cognitive and Psychosocial Improvements Following Aripiprazole Augmentation of SSRI Antidepressant Therapy in Treatment Refractory Depression: A Pilot Study. 2013 , 02, 45-53		4
35	A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises. <i>Psychiatry Investigation</i> , 2014 , 11, 371-9	3.1	9
34	Aripiprazole Induced Acute Transient Bilateral Myopia: A Case Report. <i>Balkan Medical Journal</i> , 2015 , 32, 230-2	1.5	9
33	The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2019 , 17, 495-502		8
32	Beneficial effects of adjunctive aripiprazole in major depressive disorder are not dependent on antidepressant therapy history: a post hoc analysis of 3 randomized, double-blind, placebo-controlled trials. <i>primary care companion for CNS disorders, The</i> , 2012 , 14,	1.2	2
31	Use of second generation antipsychotics for treatment-resistant major depressive disorder. <i>Mental Health Clinician</i> , 2014 , 4, 246-256	1.6	
30	Behandlung depressiver Störungen. 2016 , 1-39		
29	[The efficacy of psychopharmacotherapy of late onset depression: the optimization of treatment duration]. <i>Zhurnal Nevrologii I Psikiatrii Imeni S S Korsakova</i> , 2016 , 116, 16-27	0.4	1
28	Aripiprazole-induced transient myopia. <i>İstanbul Kuzey Klinikleri</i> , 2020 , 7, 516-518	0.8	1
27	Antipsychotic Drugs. 2019 ,		
26	Antipsychotic Drugs. 2019 ,		
25	Effects of Discontinuation of Drugs Used for Augmentation Therapy on Treatment Outcomes in Depression: A Systematic Review and Meta-analysis. <i>Pharmacopsychiatry</i> , 2021 , 54, 106-116	2	0
24	The Dopamine D2 Receptor Partial Agonist Antipsychotics, Aripiprazole, and Brexpiprazole. 2021 , 1-45		
23	Late-Life Depression Treatment: the State of the Art. <i>Psychiatry</i> , 2020 , 18, 95-107	0.4	
22	The Black Book of Psychotropic Dosing and Monitoring. <i>Psychopharmacology Bulletin</i> , 2018 , 48, 64-153	0.9	1
21	Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Psychopharmacology Bulletin</i> , 2018 , 48, 62-80	0.9	10

20	Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: preliminary findings based on a systematic review and dose-effect meta-analysis.. <i>British Journal of Psychiatry</i> , 2021 , 1-8	5.4	1
19	Convergence of Clinically Relevant Manipulations on Dopamine-Regulated Prefrontal Activity Underlying Stress Coping Responses.. <i>Biological Psychiatry</i> , 2021 ,	7.9	2
18	Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
17	Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A CAN-BIND Study.. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2022 ,	3.4	
16	Augmentation Strategies For Treatment Resistant Major Depression: A Systematic Review And Network Meta-Analysis.. <i>Journal of Affective Disorders</i> , 2022 ,	6.6	7
15	Efficacy and safety of adjunctive serotonin-dopamine activity modulators in major depression: A meta-analysis of randomized controlled trials.. <i>Journal of Clinical Pharmacology</i> , 2021 ,	2.9	2
14	Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy.. <i>Brain and Behavior</i> , 2022 , e2555	3.4	1
13	Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia.. <i>European Journal of Medicinal Chemistry</i> , 2022 , 233, 114218	6.8	1
12	Depression and Anxiety Disorders. 305-450		
11	The burden associated with, and management of, difficult-to-treat depression in patients under specialist psychiatric care in the United Kingdom.. <i>Journal of Psychopharmacology</i> , 2022 , 2698811221090628	4.6	0
10	Recent advances in dopamine D 2 receptor ligands in the treatment of neuropsychiatric disorders.		1
9	Amitriptyline and Depressions. 2022 , 1205-1223		0
8	The Dopamine D2 Receptor Partial Agonist Antipsychotics, Aripiprazole, and Brexpiprazole. 2022 , 1977-2021		0
7	Inflammatory monocyte gene signature predicts beneficial within group effect of simvastatin in patients with schizophrenia spectrum disorders in a secondary analysis of a randomized controlled trial. 2022 , 26, 100551		0
6	A head-to-head randomised controlled trial of aripiprazole versus quetiapine as augmenting agents in treatment-resistant depression. 2022 , 12, 307		0
5	Early-Onset Effectiveness of Adjunctive Aripiprazole in Patients With Depression With Inadequate Response to First-Line Antidepressants. 2022 , 52, 518-526		0
4	Einsatz von Antipsychotika, Antikonvulsiva, Stimulantien, Benzodiazepinen und Hypnotika bei therapieresistenten Depressionen. 2022 , 119-134		0
3	Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. 2023 , 180, 190-199		1

- 2 Rethinking the medication management of major depression. **2023**, 23, 331-363 ○
- 1 Pharmacotherapy for Treatment-Resistant Depression. **2023**, ○